Insmed Inc to Discuss Topline Data from TPIP Phase 1 Study Conference Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Insmed TPIP's Phase I Data Call. (Operator Instructions) I would now like to hand the conference over to your speaker today, Eleanor Barisser. Thank you. Please go ahead.
Thank you, Megan. Good morning, and welcome to today's conference call to discuss our Phase I top line results for Treprostinil Palmitil Inhalation Powder.
Before we start, let me remind you that today's call will include forward-looking statements based on current expectations. Such statements represent our judgment as of today and may involve risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements. Please refer to our filings with the Securities and Exchange Commission, which are available through the SEC's website at www.sec.gov or from our website for information concerning the risk factors that could affect the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |